Precautions when using evantumumab

Amivantamab (amivantamab-vmjw), as an innovative drug, has shown efficacy in the treatment of non-small cell lung cancer. However, like other medications, its use comes with its own set of warnings and precautions. The following are several aspects that must be paid attention to when using evantumumab:

1. Prevention and treatment of infusion-related reactions

During the infusion of evantumumab, patients may experience a series of reactions, including dyspnea, flushing, fever, etc. To reduce the likelihood of these reactions, patients need to be pretreated before infusion, such as with antihistamines, antipyretics, and corticosteroids. At the same time, the patient's reaction should be closely monitored during the infusion process. If any abnormality occurs, the infusion should be interrupted immediately, and the infusion rate should be adjusted or the drug should be discontinued according to the severity of the reaction.

2. Interstitial lung disease/Risk of pneumonia

Interstitial lung disease/Pneumonitis is a side effect that requires special vigilance during evantumumab treatment. Patients should be closely monitored for new or worsening respiratory symptoms during treatment. Once ILD/pneumonitis is suspected in a patient, the drug must be stopped immediately and further examination and treatment must be performed.

3. Response to adverse skin reactions

Evantumumab may cause a variety of skin problems, such as rash, itching, and dry skin. Therefore, patients should avoid overexposure to the sun during treatment and are advised to use sunscreen and moisturizer to protect their skin. Skin reactions that occur should be treated promptly with topical corticosteroids and antibiotics.

4. Pay attention to the possibility of eye toxicity

Patients taking evantumumab also need to be aware of the risk of ocular toxicity, which may include keratitis, dry eye symptoms, etc. Patients should promptly report any eye discomfort to their doctor so that it can be treated promptly.

5. Warnings for pregnant and lactating women

Based on animal experiments and drug mechanism studies, evantumumab may cause damage to embryos and fetuses. Therefore, female patients of childbearing potential must take effective contraceptive measures during treatment and for a period after discontinuation of treatment. At the same time, lactating women should also avoid breastfeeding while taking the medication.